Read more

February 03, 2020
1 min read
Save

FDA approves Seqirus’ pandemic H5N1 flu vaccine, Audenz

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

The FDA announced the approval of a vaccine to protect against pandemic influenza A(H5N1).

Perspective from Amesh A. Adalja, MD

Audenz (Seqirus) is the first-ever adjuvanted, cell-based vaccine designed to protect against H5N1 in the event of a pandemic, according to Seqirus. It was approved for children aged 6 months or older.

“The approval of Audenz represents a key advance in influenza prevention and pandemic preparedness, combining leading-edge cell-based manufacturing and adjuvant technologies,” Seqirus Chief Scientist and Senior Vice President of Research and Development Russell Basser, MD, said in a news release. “This pandemic influenza vaccine exemplifies our commitment to developing innovative technologies that can help provide rapid response during a pandemic emergency.”

The MF59-adjuvanted vaccine is designed to be rapidly deployed to help protect the U.S. population from H5N1 and can be stockpiled for first responders in the event of a pandemic, Seqirus noted.

Influenza pandemics can occur when a novel influenza virus emerges in the human population. Experts have identified H5N1 — a highly pathogenic virus in poultry — as one of the likeliest potential threats.

According to Seqirus, Audenz will be produced in a Holly Springs, North Carolina, facility that was built and supported through a multiyear public-private partnership between Seqirus and the Biomedical Advanced Research and Development Authority (BARDA). Seqirus said it can produce the vaccine on a pandemic scale because of its partnership with BARDA.

“Pandemic influenza viruses can be deadly and spread rapidly, making production of safe, effective vaccines essential in saving lives. . . ,” BARDA Director Rick Bright, PhD, said in the release. “Ultimately, this latest licensure means we can protect more people in an influenza pandemic.” – by Ken Downey Jr.

Reference:

Sequirus. Sequirus announced U.S. FDA approval of its first-ever adjuvanted, cell-based pandemic influenza A (H5N1) vaccine. https://www.seqirus.us/news/seqirus-announces-us-fda-approval-of-pandemic-influenza-vaccine. Accessed February 3, 2020.